Not Yet RecruitingPhase 2

Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

United States1 participantsStarted 2026-04-01

Plain-language summary

The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Known patient with PHP1a (confirmed GNAS mutation) * Optimized therapy for diabetes and dyslipidemia Exclusion Criteria: \- Use of medications that may affect endpoints that are changed within 3 months prior to Baseline or that are likely to require a change in dose during the open-label treatment period

What they're measuring

Greater than or Equal to 5% Weight loss

Timeframe: Baseline to 6 Months

Trial details

NCT IDNCT07496463

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-01

Contact for this trial

Lindsay T. Fourman, MD

617-643-4590 lfourman@mgb.org

View on ClinicalTrials.gov More Pseudohypoparathyroidism Type 1a trials